Subscribe
istock-509483224-pills-1
txking / iStockphoto.com
9 January 2018Americas

Celgene files TM claim against Beacon over psoriasis drug

Global biopharmaceutical company Celgene Corporation, headquartered in New Jersey, has filed a claim against oncology company Beacon Pharmaceuticals, situated in Bangladesh, for trademark infringement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.

More on this story

Big Pharma
Amgen announces $13.4bn acquisition of Celgene psoriasis treatment
27 August 2019   Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, for $13.4 billion.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC